Stifel Nicolaus Cuts Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00

Repare Therapeutics (NASDAQ:RPTX) had its price target decreased by Stifel Nicolaus from $9.00 to $4.00 in a research note issued to investors on Friday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Friday, November 8th.

Repare Therapeutics Trading Down 55.4 %

NASDAQ RPTX opened at $1.77 on Friday. The business has a fifty day simple moving average of $3.30 and a 200 day simple moving average of $3.35. Repare Therapeutics has a 12 month low of $1.66 and a 12 month high of $8.49. The firm has a market capitalization of $75.24 million, a P/E ratio of -0.89 and a beta of 0.71.

Hedge Funds Weigh In On Repare Therapeutics

Several large investors have recently modified their holdings of RPTX. Barclays PLC boosted its stake in Repare Therapeutics by 1,471.7% in the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after purchasing an additional 7,800 shares during the period. Vontobel Holding Ltd. lifted its holdings in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after buying an additional 4,000 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Repare Therapeutics in the second quarter valued at approximately $110,000. Exchange Traded Concepts LLC grew its stake in Repare Therapeutics by 21.2% during the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after acquiring an additional 8,809 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after acquiring an additional 13,800 shares during the period. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.